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Background: The aim of this study was to determine which combination of personal, disease-related and environmental
factors is best associated with at-work productivity loss in patients with rheumatoid arthritis (RA), and to determine
whether at-work productivity loss is associated with the quality of life for these patients.
Methods: This study is based on cross-sectional data. Patients completed a questionnaire with personal,
disease-related and environmental factors (related to the work environment), and clinical characteristics were
obtained from patient medical records. At-work productivity loss was measured with the Work Limitations
Questionnaire, and quality of life with the RAND 36. Using linear regression analyses, a multivariate model was
built containing the combination of factors best associated with at-work productivity loss. This model was
cross-validated internally. We furthermore determined whether at-work productivity loss was associated with
quality of life using linear regression analyses.
Results: We found that at-work productivity loss was associated with workers who had poorer mental health,
more physical role limitations, were ever treated with a biological therapeutic medication, were not satisfied
with their work, and had more work instability (R2 = 0.50 and R2 following cross-validation was 0.32). We found
that at-work productivity loss was negatively associated with health-related quality of life, especially with
dimensions of mental health, physical role limitations, and pain.
Conclusions: We found that at-work productivity loss was associated with personal, work-related, and clinical
factors. Although our study results should be interpreted with caution, they provide insight into patients with
RA who are at risk for at-work productivity loss.
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Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease with an impact on daily activities such as work [1].
The impact on work can be profound since permanent
work disability (inability to continue working), is com-
mon among patients with RA [2]. In addition to the
consequences for the patient, such as a decreased quality
of life, work disability also leads to high costs. Approxi-
mately one-third of the total cost for patients with RA is* Correspondence: crl.boot@vumc.nl
1Department of Public and Occupational Health, EMGO Institute for Health
and Care Research, VU University Medical Center, Amsterdam, the
Netherlands
2Body@Work, Research Center Physical Activity, TNO-VU University Medical
Center, Amsterdam, the Netherlands
Full list of author information is available at the end of the article
© 2015 van Vilsteren et al.; licensee BioMed C
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.caused by production losses [3]. Production losses in-
clude both lost work hours and times when patients are
working, but their ability to meet work demands is lim-
ited (at-work productivity loss). Recently, the greatest
impact on costs for patients with RA was shown to be
reduced performance while working (at-work productiv-
ity loss), followed by wage loss from quitting or changing
jobs, decreased working hours, and missed work days
(sick leave) [4]. This implies that at-work productivity
loss is an important concern, since work hours are not
only lost incidentally through sick leave, but also more
structurally and profoundly by at-work productivity loss.
Predictors for permanent work disability have been stud-
ied extensively and highlight the importance of personal
factors such as education level and age, as well as disease-entral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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limitations in daily activities caused by the disease [5,6]. In
contrast, predictors for sick leave and at-work productivity
loss have not been well researched, although interest in at-
work productivity loss has been increasing since 49% of pa-
tients with RA have this experience [4]. The importance of
at-work productivity loss has been recognized by the
OMERACT (Outcome Measures in Rheumatology) initia-
tive [7] and recently, measures for at-work productivity loss
have been identified and validated [8-10]. Since measures
for at-work productivity loss are now available, it is possible
to investigate the work functioning of patients with RA.
Until now, little has been known about the at-work prod-
uctivity loss of this patient population [11]. Knowledge
about factors associated with at-work productivity loss is
needed to prevent both this loss and the possibility of leav-
ing employment permanently in the future for patients with
RA [12]. Therefore, it is vital to identify patients with RA
who are at risk for at-work productivity loss in an early stage.
Prolonging work participation reflects an important
contribution to fulfilling societal roles. It has been sug-
gested that becoming permanently work-disabled is as-
sociated with a poorer quality of life in general [13-15].
Since patients who experience at-work productivity loss
are prone to develop sick leave and permanent work dis-
ability in the future, we hypothesize that at-work prod-
uctivity loss is associated with a low quality of life. This
study has two research questions:
(1)Which combination of personal, disease-related and
environmental factors is best associated with at-
work productivity loss in patients with RA?
(2)Is at-work productivity loss associated with a low
quality of life in patients with RA?
Methods
Design
This is a cross-sectional study of the baseline measure-
ments of a randomised controlled trial (RCT) evaluating
an intervention program to support at-work productivity
for workers with RA. The RCT design is described in de-
tail elsewhere [16]. Patients with RA were recruited from a
specialized rheumatology clinic (Reade, formerly the Jan
van Breemen Institute), regional hospitals (outposts of
Reade), and an academic hospital (the VU University Med-
ical Center, department of rheumatology), Amsterdam, the
Netherlands.
Inclusion criteria for this study were: (1) a diagnosis of
RA, (2) ages 18-64 years, (3) having a paid job (either
paid- employment or self-employed), (4) working at least
eight hours per week, (5) and experiencing at least
minor difficulties in functioning at work. We asked pa-
tients to indicate on a scale of one to five the extent that
RA interfered with their work functioning. Patients whoindicated one on this scale, had a severe comorbidity,
were unable to read or understand Dutch, or had had
more than three months of sick leave at the time of in-
clusion were excluded. The study was approved by the
medical ethics committees of the participating centres
(Slotervaart Hospital, Reade, and the VU University
Medical Center), and all patients gave written informed
consent.
Measurements
Patients completed a questionnaire and their clinical
characteristics were obtained from their medical records.
All measured variables were categorized into either in-
ternal (personal or disease-related variables) or external
factors related to the external environment.
Outcome measures
At-work productivity loss was measured by hours lost
from work due to presenteeism. Presenteeism is defined
as being present at the job, but not being able to func-
tion optimally. Presenteeism was measured using the 25-
item Work Limitations Questionnaire (WLQ) [17]. The
WLQ includes four dimensions; physical demands, time
management, mental-interpersonal demands, and output
demands [18]. Based on these four dimensions, a score
was calculated to represent the percentage of productiv-
ity loss. This score was multiplied by the number of
work hours in two weeks, leading to an estimation of
the number of hours that a patient had not been fully
productive at work over the last two weeks. The internal
consistency is high for the WLQ, with a Cronbach’s
alpha of 0.88 [19]. Several studies showed that the WLQ
is a reliable and valid questionnaire for assessing prod-
uctivity loss in workers with RA [18-20].
Quality of life was measured using the RAND 36
[21,22]. All nine subscales of the RAND 36 were in-
cluded in the questionnaire, and used for further ana-
lyses including mental health (Cronbach’s α 0.85), pain
(α 0.88), physical role limitations (α 0.90), physical func-
tioning (α 0.92), social functioning (α 0.71), vitality (α
0.82), emotional role limitations (α 0.86), general health
perception (α 0.81), and perceived health change (α not
applicable). The subscales of the RAND 36 are trans-
formed into a scale score ranging from 0-100. A higher
score indicates better health. The subscales of the RAND
36 are included as internal factors in the analysis.
Internal factors
The Disease Activity Score of 28 joints (DAS28) was
assessed as part of usual care and was collected from pa-
tient records. The DAS28 score was based on the num-
ber of tender and swollen joints out of 28 joints, the
erythrocyte sedimentation rate (ESR) and the patient’s
general health measured on a visual analogue scale
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modifying antirheumatic drugs (DMARD) and the use of
biological therapeutics. Serological measures (anti-cyclic
citrullinated peptide antibodies [aCCP] and IgM
rheumatoid factor [IgM-RF]) were recorded as positive
or negative.
Daily functioning was measured with the Health As-
sessment Questionnaire (HAQ), a reliable and valid
questionnaire widely used in RA research [24]. The
HAQ score ranges from 0-3; a higher score indicates in-
creased disability.
Pain and fatigue were measured with single items
using VAS scales [25,26]. VAS scales range from 0-10,
with 0 meaning no pain/ fatigue at all, and 10 meaning
severe pain/ very tired.
The presence of comorbidity (yes/no) was investigated
using a list with 15 common comorbidities including
cardiovascular diseases, diabetes mellitus, and psycho-
logical disorders. Disease duration was determined by
one open-ended question about the year of the patient’s
RA diagnosis, and the duration of complaints due to RA
(answer categories were 0-2 years, 3-5 years, 6-10 years,
>10 years). We included one question about the highest
attained educational level. Low education was operational-
ized as primary school, middle education or basic voca-
tional education. Middle education was operationalized as
secondary vocational education or intermediate vocational
education. High education was operationalized as higher
vocational education or a university degree. The patients’
gender and age were collected from patient medical
records.External factors
We measured supervisor and co-worker support,
psychological and physical job demands with subscales
from the Job Content Questionnaire (JCQ) [27]. Items
of the JCQ such as ‘My colleagues are friendly’ are an-
swered on a scale of 1 (totally disagree) to 4 (completely
agree). The score of each subscale ranges from 1-4 with
a higher score indicating more supervisor support, co-
worker support, etc.
Work instability was measured with the RA Work In-
stability Scale (RA WIS) [28,29]. The RA WIS contains
23 items (yes/no), which are summed for a total score
ranging between 0-23. A score of 0-9 indicates low, 10-
17 moderate, and 18-23 high work instability.
Sick leave was measured with a single item of the
Productivity and Disease Questionnaire (Prodisq) [30].
Patients were asked to count the number of days they
had been absent from work during the last 12 months.
Three single item questions about being a supervisor
(yes/no), shift work (yes/no), and type of job contract
(permanent contract/self-employed) were included inthe questionnaire worded as The Netherlands Working
Conditions Survey [31].
Statistical analyses
For the first aim, we determined which combination of
factors was best associated with the outcome of at-work
productivity loss using linear regression models. These
models were built on a dataset of 100 randomly selected
participants. The remaining 50 patients were used to
cross-validate our model.
In step 1, we performed univariate linear regression
analyses for each independent variable with at-work
productivity loss. We did not include the number of
working hours as an independent variable, since the
number of work hours is already incorporated in the
WLQ score for at-work productivity loss. Independent
variables with a p-value <0.15 were selected for further
analyses [32]. In step 2, we built a multivariate model for
the nine subscales of the RAND 36, using a backward
stepwise procedure, because the subscales are highly cor-
related. Similarly we built a backward multivariate model
for the DAS 28 score and its four components that were
highly correlated as well. We retained the components
with a p-value <0.15 for further analyses.
In step 3, we built two multivariate models; one multi-
variate model for the selected internal variables and one
model for the selected external variables. All independ-
ent variables selected in step 1 and 2 were entered in the
models, using a backward stepwise procedure. Variables
with a p-value <0.15 were retained in the multivariate
models, resulting in an internal and external model. In
step 4, one final model was built in which all variables
retained in the internal and external model in step 3
were entered again using a backward procedure. Vari-
ables with a p-value <0.05 were retained in the final
model. R2 was used to calculate the proportion of ex-
plained variance.
The final model was cross-validated in the
remaining sample of n = 50 by calculating the R2 of
the final model applied to the sample of n = 50. R2 was
calculated by determining the correlation between the
actual outcome measured with the questionnaire, and
the outcome calculated based on the regression coeffi-
cients in the final multivariate model of step 4 (i.e.
outcome calculated = constant + B1 * var1, etc.). The
R2 of both samples (n = 100 and n = 50) were
compared.
For the second aim of this study, univariate linear re-
gression analyses were performed to gain insight into
the crude associations between at-work productivity loss
and quality of life. The independent variables were each
subscale of the RAND 36 retained in the backward pro-
cedure from step 2, and the dependent variable was at-
work productivity loss. Second, we investigated potential
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with a p-value <0.15 with at-work productivity loss were
considered as potential confounders. Confounders were
selected based on a stepwise forward strategy. Each po-
tential confounder was entered separately into the
model. The strongest confounder based on the change
in the regression coefficient was retained in the model,
and subsequently, all remaining potential confounders
were entered one by one. The strongest confounder was
retained from each round, until the regression coeffi-
cient did not change significantly by adding the next
confounder. A change in the regression coefficient of
more than 10% was considered significant [32].
All analyses were performed in SPSS version 20.
Results
Baseline measurements were available for 150 partici-
pants. Tables 1, 2 and 3 describe the characteristics ofTable 1 Association of internal factors with at-work productiv









Time since diagnosis 10.4 (8.9)
Duration of complaints >10 years 47.3a
Comorbidity present 64.7a
Pain (0-10b) 3.72 (2.50)
Fatigue (0-10b) 4.59 (2.53)
Health Assessment Questionnaire (0-3b) 0.79 (0.55)
Quality of life dimensions
(RAND 36) (0-100b):
- Mental health 77.2 (14.5)
- Pain 64.6 (17.8)
- Physical role limitations 48.0 (40.3)
- Physical functioning 67.1 (21.5)
- Social functioning 71.4 (21.4)
- Vitality 54.3 (18.5)
- Emotional role limitations 78.6 (37.1)
- General health perception 50.8 (17.3)
- Perceived health change 51.7 (26.7)
a.Expressed as n(%).
b.Range of the scale on which the score was based.
c.Item was not retained based on the second analyses step (multivariate models forthe study population. In general, women participated in
this study (84.0%). The mean age of the study population
was 49.7 years, and on average, our participants had
been diagnosed with RA 10.4 years ago. The overall
WLQ score was 7.1, meaning that 7.1% of the time dur-
ing the past two working weeks had been lost due to lost
work productivity. This finding led to an average esti-
mate of 4.0 work hours lost due to presenteeism over
two weeks, based on an average work week of 28.7 hours.
The study population scored low on the RAND 36 scales
for vitality, physical role limitations, general health per-
ception, and perceived health change scales, indicating
that they had worse health on these subscales compared
to the other RAND 36 subscales.
Following univariate regression analyses (Tables 1, 2
and 3), we built multivariate models for internal and ex-
ternal factors. In the internal model, we retained mental
health, pain, physical role limitations and biologicality loss for workers with RA
At-work productivity loss
Univariate N = 150
B 95% CI p-value
-0.03 -0.08; 0.03 0.36





-0.02 -1.28; 1.23 0.87
0.71 -0.47; 1.89 0.24
-0.03 -0.08; 0.02 0.25
0.04 -0.87; 0.95 0.93
-0.17 -1.12; 0.78 0.73
0.18 -0.002; 0.36 0.05
0.27 0.10; 0.44 <0.01
0.69 -0.14; 1.53 0.10
-0.10 -0.13; -0.08 <0.01
-0.05 -0.07; -0.02 <0.01
-0.03 -0.04; -0.02 <0.01
-0.02c -0.04; 0.002 0.08
-0.06c -0.08; -0.04 <0.01
-0.06c -0.08; -0.04 <0.01
-0.03c -0.04; -0.02 <0.01
-0.04c -0.06; -0.01 <0.01
-0.02c -0.04; -0.01 0.01
the RAND36 subscales).
Table 2 Association of clinical factors with at-work productivity loss for workers with RA
Baseline characteristics N = 150 At-work productivity loss
Univariate N = 150
Mean (sd) B 95% CI p-value
Clinical factors
DAS score 28 joints 2.70 (1.23) 0.57 0.20; 0.94 <0.01
- Swollen joints 1.01 (2.01) 0.19c -0.04; 0.41 0.10
- Tender joints 2.11 (3.10) 0.14c -0.01; 0.28 0.06
- ESR 12.8 (13.0) 0.03c -0.004; 0.06 0.09
- VAS general health (0-100b) 34.5 (22.5) 0.03c 0.01; 0.05 0.01
Number of DMARDS used since diagnosis 2.13 (1.05) 0.29 -0.15; 0.72 0.19
Number of DMARDS used during last year 1.10 (0.70) 0.19 -0.49; 0.87 0.58
Biological therapeutic used since diagnosis; yes 47.3a 0.86 -0.05; 1.77 0.06
Biological therapeutic used during last year; yes 34.5a 0.34 -0.62; 1.31 0.48
RF positive 61.7a 0.08 -0.86; 1.02 0.87
aCCP positive 65.1a 0.13 -0.81; 1.07 0.79
DAS: Disease Activity Score; ESR: Erythrocyte Sedimentation Rate; VAS: Visual Analogue Scale; DMARD: Disease-modifying Antirheumatic Drug; RF:
Rheumatoid Factor; aCCP: Anti-cyclic Citrullinated Peptide Antibodies.
a.Expressed as n(%).
b.Range of the scale on which the score was based.
c.Item was not retained based on the second analyses step (multivariate model for the DAS components).
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the external model, we retained the variables for having
a job contract, being a supervisor, limitations in func-
tioning at work, job satisfaction, work instability, heavy
and demanding work, and having both physical and
mental job demands for further analyses.
The final model (Table 4) shows that participants who
experienced worse mental health and more physical role
limitations, who had been treated with a biological
therapeutic since diagnosis, who were not or only mod-
erately satisfied with their work, and had a higher work
instability score experienced more at-work productivity
loss. The R2 for this model was 0.50. The R2 of this
model in the cross-validation sample was 0.32.
For the second aim of our study, more at-work prod-
uctivity loss was significantly associated (ß -0.10, 95% CI
-0.13; -0.08) with worse mental health (Table 5). The ad-
justed analysis showed a regression coefficient of -0.06
(95% CI -0.09; -0.03), meaning that more at-work prod-
uctivity loss was associated with worse mental health.
The crude analysis of at-work productivity and the qual-
ity of life dimension for physical role limitations had a
regression coefficient of -0.03; the adjusted analysis had
a regression coefficient of -0.01. This means that on the
physical role limitations scale (0-100, where a higher
score indicates fewer role limitations) for every 10 points
lower on the scale, an additional 0.1 hours are lost due
to presenteeism. At-work productivity loss was signifi-
cantly associated (ß -0.05, 95% CI -0.07; -0.02) with
more pain. The adjusted analysis showed a regressioncoefficient of -0.03, 95% CI -0.06; 0.003), meaning that
more at-work productivity loss is associated with more
pain.
Discussion
In this study, we showed that workers with RA lose
4.0 hours of productive work per two weeks on average
due to at-work productivity loss based on an average
work week of 28.7 hours. At-work productivity loss for
workers with RA is associated with both internal and ex-
ternal factors. Workers with worse mental health and
more physical role limitations reported more lost hours
at work due to presenteeism, as did workers who had
ever been treated with a biological therapeutic, who were
not satisfied with their work, and those with more work
instability. We also showed that at-work productivity
loss is negatively associated with health-related quality
of life, especially in the dimensions of mental health,
physical role limitations, and pain. This means that a
lower quality of life on these subdomains is associated
with more lost hours due to presenteeism.
Comparison with other studies
Only a few studies have reported on factors associated
with at-work productivity loss for workers with RA. In a
study by Geuskens et al. on workers with early inflam-
matory joint conditions, it was shown that at-work prod-
uctivity loss was predicted by low support from
colleagues, intermediate levels of pain, poor physical
functioning and poor mental health [11]. Gignac et al.
Table 3 Association of external factors with at-work productivity loss for workers with RA
Baseline characteristics N = 150 At-work productivity loss
Univariate N = 150
Mean (sd) B 95% CI p-value
External factors
Permanent or temporary job contract 82.7a -1.24 -2.41; -0.08 0.04
Being a supervisor (yes) 27.5a 0.98 -0.03; 2.00 0.06
Multiple jobs (yes) 16.8a -0.04 -1.16; 1.08 0.95
Shift work (yes) 18.8a 1.07 -0.08; 2.21 0.07
Limited in functioning at work: Overall p-value: <0.01
No 13.3a Ref. Ref. Ref.
Slightly 76.0a 2.14 0.85; 3.42 <0.01
Strongly 10.7a 2.66 0.89; 4.44 <0.01
Supervisor social support (1-4b) 2.99 (0.62) 0.35 -0.34; 1.03 0.32
Decision authority (1-4b) 2.70 (0.36) 0.24 -1.03; 1.49 0.71
Psychological job demands (1-4b) 2.65 (0.31) -0.04 -1.54; 1.47 0.96
Physical job demands (1-4b) 1.98 (0.61) 0.63 -0.11; 1.37 0.09
Co-worker social support (1-4b) 3.09 (0.46) 0.22 -0.77; 1.21 0.67
Not or moderately satisfied with work 31.3a 2.35 1.47; 3.24 <0.01
Work instability (0-23b) 8.87 (4.80) 0.28 0.20; 0.36 <0.01
Sick leave during last 12 months 0.46 0.17; 0.75 <0.01
Heavy demanding work 70.7a 1.01 0.04; 1.98 0.04
Work demands: Overall p-value: 0.25
Mental 66.7a Ref. Ref. Ref.
Both physical and mental 21.3a 0.99 -0.18; 2.15 0.10
Physical 12.0a 0.11 -1.29; 1.52 0.87
Treatment center: Overall p-value: 0.12
Specialized rheumatology center 76.7a Ref. Ref. Ref.
Academic hospital 10.0a -0.94 -2.40; 0.52 0.21
Regional hospitals 13.3a -1.22 -2.54; 0.10 0.07
a.Expressed as n(%).
b.Range of the scale on which the score was based.
Table 4 Factors associated with at-work productivity loss
for workers with RA
Factor Multivariate N =
100
B 95% CI
Mental health -0.06 -0.09 :
-0.02
Physical role limitations -0.01 -0.03;
-0.002
Biological therapeutic used since
diagnosis; yes
1.06 0.25; 1.87
Not or moderately satisfied with work 1.00 0.08; 1.92
Work instability 0.10 0.001;
0.21
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meet work demands) in workers with inflammatory arth-
ritis or osteoarthritis [12]. Job disruptions were associ-
ated with male sex, previous absenteeism, job change,
and arthritis-work spill over (the extent to which the de-
mands of arthritis interfered with work and work inter-
fered with managing arthritis). In line with these studies,
we found both internal and external factors related with
at-work productivity. Our results show that at-work
productivity loss was not only associated with physical
functioning, but also with mental health, as was also
found by Geuskens et al [11].
Only one clinical factor was retained in our final model
in this study (use of biological therapeutics). We found
that patients who had used a biological therapeutic since





Dependent variable: at-work productivity loss
Crude analysis Adjusted analysis
ß 95% CI ß 95% CI
Mental health -0.10 -0.13; -0.08 -0.06a -0.09; -0.03
Physical role limitations -0.03 -0.04; -0.02 -0.01b -0.02; 0.0004
Pain -0.05 -0.07; -0.02 -0.03c -0.06; 0.003
a.Adjusted for work instability and job satisfaction.
b.Adjusted for work instability, mental health, HAQ, pain (RAND 36), and job contract.
c.Adjusted for work instability, pain (VAS), physical role limitations, mental health, and HAQ.
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productivity loss. Although a recent review showed that
the use of biological therapeutics had a potentially benefi-
cial effect on work participation [33]. Longitudinal studies
included in this review generally concerned patients with
high disease activity or DMARD failure. In our study, we
did not select patients based on indicators of disease activ-
ity. Our findings suggest that the use of biological thera-
peutics may not only be considered as more effective
medication for patients with higher disease activity
[34-36], but also as a marker of more severe disease. Ac-
cording to this criterion, patients in the present study
probably have a higher than average disease severity, since
the use of biologicals ever was 47.3%, whereas the total
population with RA at Reade has a present biological use
of 25% (according to internal communication with rheu-
matologists of the participating centres).
Two external factors were associated with at-work
productivity loss: work instability and low job satisfac-
tion. Work instability indicates a mismatch between
functional ability and job demands [28]. In addition to
the association of more work instability with more at-
work productivity loss in our study, work instability was
also shown to predict work transitions for patients with
RA in another study [37]. Work transitions include re-
ductions in work hours, sickness absence, job changes,
and temporary employment. These findings, as well as
our study results, show the potential prognostic value of
the variable work instability on work-related outcomes.
The importance of job satisfaction for work participation
has been documented. In a study on chronic low back
pain, moderate or poor job satisfaction predicted longer
work absences [38].
We found that at-work productivity loss was associ-
ated with low quality of life. This association was most
profound on the mental health dimension, indicating
that worse mental health is associated with more at-
work productivity loss, which is in line with previous re-
search [11]. An earlier study on patients with psoriatic
arthritis showed that work-disabled patients experience
worse mental health compared to working patients [14].
This finding indicates that actually having a paid job hasa positive influence on mental health. In our study of
working patients with RA, we found that the mean scale
score on the mental health scale of the RAND 36 was
comparable to the Dutch normal value for this subscale
[22]. Although our population on average did not have
impaired on mental health, mental health remains a
topic of concern, since for our patients with RA, worse
mental health was associated with more at-work prod-
uctivity loss.
We validated our multivariate model in our population
(internal validation) [39]. In previous studies, multivari-
ate models have been mainly used for dichotomous out-
comes (i.e. sick/ not sick). For dichotomous multivariate
models, two studies performed an internal validation of
their model [40,41]. They compared, amongst others, R2
values that were comparable (<10% change in R2) be-
tween the multivariate model and validation model
[40,41]. For prediction models with continuous out-
comes, there are no validation studies available to our
knowledge. Our R2 in the main sample was 0.50, and
0.32 in our validation sample. This decline indicates that
the factors best associated with at-work productivity loss
should be interpreted cautiously.
Strengths and limitations
A strength of our study was that we included a variety
of both internal and external factors in our analyses, in-
stead of focusing on clinical factors only, for example.
The average number of work hours lost due to present-
eeism is in line with previous research. In a study by
Zhang et al. who also measured at-work productivity
loss with the WLQ, 4.0 hours were lost every two weeks
due to presenteeism, although the average number of
work hours was 35 hours per week in their study, com-
pared to 28.7 hours in our study [42]. This supports the
representativeness of our study sample.
A limitation is that our results are based on cross sec-
tional data, therefore, we cannot distinguish causes and
consequences.
Our results concern workers with RA who experi-
enced at least minor difficulties at work. We were there-
fore not able to study the incidence of presenteeism.
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can introduce recall bias. From previous research how-
ever, it seems that self-reports of sick leave are accurate
when compared to sick leave registries [43].Study implications
Further research should focus on work functioning, and
predictors for at-work productivity loss in cohort (longi-
tudinal) studies to identify those patients most at risk.
Our results give an indication of risk factors for at-
work productivity loss, but further investigation is
needed for more robust findings. Since patients experi-
encing at-work productivity loss are at risk for sick leave
and permanent work disability, it is important to know
which factors contribute to at-work productivity loss, in
order to develop interventions to improve at-work prod-
uctivity loss and thereby prevent work disability. We in-
cluded a broad range of potential factors, such as
personal factors, clinical characteristics, and work-
related factors in our analysis. Our multivariate model
shows that the factors best associated with at-work
productivity loss are drawn from all three domains. Fu-
ture research should consider the potential impact of
both personal and work-related factors in addition to
clinical characteristics.
The importance of personal and work-related factors
should also be acknowledged in current clinical practice
if the goal is to enhance work participation. This means
that treating physicians should not only focus on im-
proving disease severity when treating patients with RA
who are struggling to maintain work productivity, but
they should also pay attention to personal- and work-
related factors for a more holistic approach.Conclusions
In conclusion, we found that at-work productivity loss
was associated with personal, work-related, and clinical
factors for patients with RA. Low at-work productivity
was associated with a lower quality of life, especially in
the domains mental health, physical role limitations and
pain. Although our study results should be interpreted
with caution, they provide insight on which patients with
RA are at risk for at-work productivity loss.
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